Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Aurinia Pharmaceuticals Inc - Common Shares
(NQ:
AUPH
)
14.95
-0.33 (-2.16%)
Streaming Delayed Price
Updated: 3:43 PM EST, Jan 13, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
816,998
Open
15.23
Bid (Size)
14.95 (400)
Ask (Size)
14.99 (600)
Prev. Close
15.28
Today's Range
14.75 - 15.28
52wk Range
6.550 - 16.54
Shares Outstanding
128,395,927
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Aurinia Raises Guidance and Shares Are Surging— Is This Why a Major Investor Just Boosted Its Stake?
↗
December 02, 2025
A top life sciences investor is doubling down as Aurinia’s flagship therapy gains momentum—here’s what long-term shareholders should watch next.
Via
The Motley Fool
AURINIA PHARMACEUTICALS INC (NASDAQ:AUPH) Passes Louis Navellier's Strict Growth Stock Screen
↗
November 07, 2025
Aurinia Pharmaceuticals (AUPH) exemplifies a top growth stock, showing explosive earnings growth, soaring cash flow, and consistent earnings surprises.
Via
Chartmill
Performance
YTD
-2.6%
-2.6%
1 Month
-4.7%
-4.7%
3 Month
+34.7%
+34.7%
6 Month
+65.4%
+65.4%
1 Year
+92.4%
+92.4%
More News
Read More
Earnings Scheduled For November 4, 2025
↗
November 04, 2025
Via
Benzinga
Aurinia Pharmaceuticals Reports Financial Results for the Three and Nine Months Ended September 30, 2025 and Provides Update on Recent Business Progress
November 04, 2025
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Pharma Stands By Lupus Drug After FDA Official’s Retracted Post Sparks 16% Selloff — Retail Stays Bullish On Recovery
↗
September 29, 2025
Via
Stocktwits
Earnings Scheduled For July 31, 2025
↗
July 31, 2025
Via
Benzinga
A Peek at Aurinia Pharmaceuticals's Future Earnings
↗
November 03, 2025
Via
Benzinga
FDA Drug Chief George Tidmarsh Resigns After Allegations Of Power Misuse
↗
November 03, 2025
Via
Benzinga
Aurinia Pharmaceuticals to Report Financial Results for the Three and Nine Months Ended September 30, 2025 and Provide Update on Recent Business Progress on November 4, 2025
November 03, 2025
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
FDA Turmoil Spills Over To Aurinia Pharma As Lawsuit Targets Ex-Drug Review Chief — Retail Traders Cry ‘Stock Manipulation’
↗
November 02, 2025
Via
Stocktwits
Topics
Lawsuit
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) Shows Strong Growth Traits in Fundamental Analysis
↗
October 17, 2025
Via
Chartmill
Aurinia Announces Upcoming Presentations of New Data on LUPKYNIS® at American College of Rheumatology Convergence and American Society of Nephrology Kidney Week 2025
October 15, 2025
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Responds to Now Retracted LinkedIn Post
September 29, 2025
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
12 Health Care Stocks Moving In Monday's After-Market Session
↗
September 29, 2025
Via
Benzinga
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) Passes Louis Navellier's Growth Screen
↗
September 26, 2025
Via
Chartmill
United Therapeutics Price Strength Rating Jumps After Its Stock Soared 33% Last Week On Positive Drug Test Results
↗
September 10, 2025
Via
Investor's Business Daily
Topics
ETFs
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) Shows Strong Growth Metrics and Earnings Momentum
↗
September 05, 2025
Via
Chartmill
Argenx Stock Hits Record High After Reporting 664% Earnings Surge; This Rating Upgraded
↗
August 26, 2025
Via
Investor's Business Daily
Topics
ETFs
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) Fits Louis Navellier’s High-Growth Stock Criteria
↗
August 15, 2025
Via
Chartmill
Gilead Sciences Reports Earnings Thursday. Can The Highly Ranked Drugmaker Beat Its 237% Profit Surge Last Quarter?
↗
August 04, 2025
Via
Investor's Business Daily
Aurinia (AUPH) Q2 Revenue Jumps 22%
↗
July 31, 2025
Via
The Motley Fool
Topics
Intellectual Property
Aurinia Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2025
July 31, 2025
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) – A Strong Candidate for Growth Investors
↗
July 24, 2025
Via
Chartmill
Aurinia Pharmaceuticals to Release Second Quarter 2025 Financial and Operational Results on July 31, 2025
July 22, 2025
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) – A Strong Candidate for Growth Investors
↗
July 01, 2025
Via
Chartmill
Frequently Asked Questions
Is Aurinia Pharmaceuticals Inc - Common Shares publicly traded?
Yes, Aurinia Pharmaceuticals Inc - Common Shares is publicly traded.
What exchange does Aurinia Pharmaceuticals Inc - Common Shares trade on?
Aurinia Pharmaceuticals Inc - Common Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Aurinia Pharmaceuticals Inc - Common Shares?
The ticker symbol for Aurinia Pharmaceuticals Inc - Common Shares is AUPH on the Nasdaq Stock Market
What is the current price of Aurinia Pharmaceuticals Inc - Common Shares?
The current price of Aurinia Pharmaceuticals Inc - Common Shares is 14.95
When was Aurinia Pharmaceuticals Inc - Common Shares last traded?
The last trade of Aurinia Pharmaceuticals Inc - Common Shares was at 01/13/26 03:43 PM ET
What is the market capitalization of Aurinia Pharmaceuticals Inc - Common Shares?
The market capitalization of Aurinia Pharmaceuticals Inc - Common Shares is 1.92B
How many shares of Aurinia Pharmaceuticals Inc - Common Shares are outstanding?
Aurinia Pharmaceuticals Inc - Common Shares has 2B shares outstanding.
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
